Chimeric hepatitis A vaccine
AssigneeThe United of America as represented by the Department of Health and Human Services
InventorsJeffrey I. Cohen, Robert H. Purcell, Stephen M. Feinstone, John R. Ticehurst
Life of this patent
Estimating the term…
Abstract
A full-length cDNA copy of an attenuated, cell culture-adapted hepatitis-A virus genome has been constructed. The HAV cDNA when inserted, without the oligo (dG) oligo (dC) tails, into an RNA transcription vector yielded a plasmid designated pHAV/7. Transfection of monkey kidney cells with pHAV/7 DNA yielded HAV. Transfection with RNA transcripts produced in vitro from pHAV/7 yielded about 10-fold more HAV than transfection with pHAV/7 DNA. HAV thus produced are useful as a vaccine.
Claims6
An attenuated, cell-culture adapted, infectious hepatitis A virus of the HM-175 strain produced by cells containing a nucleic acid molecule which has a nucleic acid sequence corresponding to the sequence of HAV HM-175/7 MK-5 except for the nucleotides at positions 7027 and 7425 which are those of wild-type hepatitis A virus HM-175.
An attenuated, cell-culture adapted, infectious hepatitis A virus produced by cells containing a nucleic acid molecule contained in an expression vector having ATCC deposit number 67495.
Dependencies are inferred from the claim text.